Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

This study tests a cutting-edge type of cancer immunotherapy using NK cells (natural killer cells — a type of immune cell) that have been genetically engineered to seek out and destroy cancer cells. The cells are matched to each patient based on what proteins their tumor expresses. **You may be eligible if...** - You are 18 to 75 years old - You have a confirmed advanced or metastatic solid tumor that has come back or stopped responding to standard treatment, or no standard treatment is available - Your tumor tests positive for at least one (or two, for the dual-target arm) specific surface proteins that the CAR-NK cells can target - Your overall health is good (ECOG 0-2) - You have at least one measurable tumor on imaging - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have previously received CAR-T or CAR-NK cell therapy too recently - You have an active uncontrolled infection, uncontrolled HIV, or active hepatitis B/C - You have active brain metastases requiring increasing steroids - You have active autoimmune disease on systemic immune suppression - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.